Cold Spring Harbor Laboratory (CSHL) is at the forefront of using organoid technology to study and treat cancer. Organoids are tiny 3D clusters of cells that are miniature versions of patients’ tumors.
The annual American Society of Clinical Oncology (ASCO) meeting brings together scientists from across the country who are studying every type of cancer to share the latest results from the […]
With a five-year survival rate of only 11%, pancreatic cancer patients need more effective therapies. A new form of immunotherapy is showing promise, as it shrank metastases and stopped progression […]
Neoadjuvant gemcitabine-based chemoradiotherapy prolonged OS compared with upfront surgery among patients with resectable and borderline resectable pancreatic cancer, according to phase 3 study results in Journal of Clinical Oncology.
UTSW study identifies a subset of cancer-associated fibroblasts that offers a new target to attack deadly disease and break the shield that protects pancreatic cancer from immunotherapy.
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C […]
Cancer cells can become resistant to treatments through adaptation, making them notoriously tricky to defeat and highly lethal. Cold Spring Harbor Laboratory (CSHL) Cancer Center Director David Tuveson and his […]
LA JOLLA–(June 10, 2021) In order for cancer to grow and spread, it has to evade detection by our immune cells, particularly specialized “killer” T cells. Salk researchers led by […]